| Pumilio2-deficient mice show a predisposition for epilepsy P Follwaczny, R Schieweck, T Riedemann, A Demleitner, T Straub, ... Disease Models & Mechanisms 10 (11), 1333-1342, 2017 | 56 | 2017 |
| SARS-CoV-2 and neurodegenerative diseases: What we know and what we don’t P Lingor, AF Demleitner, AW Wolff, E Feneberg Journal of Neural Transmission 129 (9), 1155-1167, 2022 | 30 | 2022 |
| Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first cerebral MRI scan B Ikenberg, AF Demleitner, T Thiele, B Wiestler, K Götze, G Mößmer, ... Stroke and vascular neurology 6 (4), 2021 | 29 | 2021 |
| Staufen2 deficiency leads to impaired response to novelty in mice B Popper, A Demleitner, VJ Bolivar, G Kusek, A Snyder-Keller, ... Neurobiology of Learning and Memory 150, 107-115, 2018 | 23 | 2018 |
| Parkinson’s disease therapy: what lies ahead? A Wolff, NU Schumacher, D Pürner, G Machetanz, AF Demleitner, ... Journal of Neural Transmission 130 (6), 793-820, 2023 | 19 | 2023 |
| Pumilio2 and Staufen2 selectively balance the synaptic proteome R Schieweck, T Riedemann, I Forné, M Harner, KE Bauer, D Rieger, ... Cell Reports 35 (12), 2021 | 19 | 2021 |
| Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials L Tzeplaeff, AV Jürs, C Wohnrade, AF Demleitner Cells 13 (5), 452, 2024 | 9 | 2024 |
| Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target L Caldi Gomes, S Hänzelmann, F Hausmann, R Khatri, S Oller, M Parvaz, ... Nature Communications 15 (1), 4893, 2024 | 8 | 2024 |
| Impact of the COVID-19 pandemic on patients with Parkinson’s disease from the perspective of treating physicians—a Nationwide cross-sectional study AW Wolff, B Haller, AF Demleitner, E Westenberg, P Lingor Brain Sciences 12 (3), 353, 2022 | 8 | 2022 |
| Long‐Lasting Impact of the COVID‐19 Pandemic on Patients with Parkinson's Disease and Their Relatives AW Wolff, B Haller, AF Demleitner, D Pürner, J Niederschweiberer, ... Movement Disorders Clinical Practice 10 (5), 819-823, 2023 | 3 | 2023 |
| Reduced tear fluid production in neurological diseases: A cohort study in 708 patients E Luib, AF Demleitner, I Cordts, E Westenberg, P Rau, D Pürner, B Haller, ... Journal of neurology 271 (4), 1824-1836, 2024 | 2 | 2024 |
| Multiomic ALS signatures highlight sex differences and molecular subclusters and identify the MAPK pathway as therapeutic target LC Gomes, S Hänzelmann, S Oller, M Parvaz, F Hausmann, R Khatri, ... bioRxiv, 2023.08. 14.553180, 2023 | 2 | 2023 |
| Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic AF Demleitner, AW Wolff, J Erber, F Gebhardt, E Westenberg, AS Winkler, ... Journal of Neural Transmission 129 (11), 1377-1385, 2022 | 1 | 2022 |
| Den Rauch riechen, bevor man das Feuer sieht–die oligosymptomatische Prodromalphase neurodegenerativer Erkrankungen A Wolff, AF Demleitner, E Feneberg, P Lingor Der Nervenarzt 95 (8), 689-696, 2024 | | 2024 |
| Smell the smoke before one sees the fire-The oligosymptomatic prodromal phase of neurodegenerative diseases A Wolff, AF Demleitner, E Feneberg, P Lingor Der Nervenarzt, 2024 | | 2024 |
| The detection of phosphorylated tau in tear fluid GD Molfetta, AF Demleitner, LAC Gomes, A Jeromin, E Vanmechelen, ... Alzheimer's & Dementia 19, e083029, 2023 | | 2023 |
| The role of Staufen 2 and Pumilio 2 in hippocampus based learning AF Demleitner lmu, 2021 | | 2021 |
| ROLE OF THE RNA-BINDING PROTEINS PUMILIO 2 AND STAUFEN 2 IN EPILEPTOGENESIS-IMPACTS ON NEUROGENESIS AND LONG-TERM MEMORY A Demleitner, P Follwaczny, R Schieweck, A Klemm, B Popper, M Kiebler EPILEPSIA 57, 153-153, 2016 | | 2016 |
